Submitted by Anonymous (not verified) on 30 October 2023 - 14:08
Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 20/11/2006, Revision: 41, Status: Authorised
Source: